Teva Pharmaceuticals (NYSE:TEVA) said that the U.S. FDA has granted fast track designation to its experimental therapy TEV-56286 (emrusolmin) for treating Multiple System Atrophy.
Emrusolmin, developed in partnership with German biotech company MODAG GmbH, is currently being tested in a phase 2 clinical trial.
Fast Track designation is designed to speed up the development and review of treatments for serious conditions with limited options, allowing closer communication with the FDA about clinical plans.
The FDA had previously granted Orphan Drug designation to emrusolmin for MSA in 2022.